Biocon Biologics secures US FDA approval for Biosimilar Bevacizumab, JOBEVNE
The approval marks Biocon Biologics’ seventh biosimilar clearance in the US, expanding its oncology portfolio in one of the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Shilpa Pharma Lifesciences’ Raichur API facility clears second consecutive FDA inspection with no…
Shilpa Medicare's Unit-2 API facility in Raichur, India passes March 2025 FDA audit without Form 483 observations, reinforcing…
Logistics4Pharma expands customs services with transit document management and bonded storage near…
Frankfurt-based Logistics4Pharma introduces a full-service customs portfolio, enhancing controlled storage and transit solutions…
FOPE and PharmaState Academy conduct session on sterile drug manufacturing under Revised Schedule M
Session 18 of the PULSE initiative focuses on regulatory compliance, operational standards, and technical readiness in sterile…
Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case
Settlement resolves allegations Jazz delayed generic Xyrem launch, driving up costs for health plans and patients
Large pharma drug licensing from China reaches record high at 28 per cent in 2024, reveals…
Innovator drug deals involving Chinese biopharma reach $41.5 billion as licensing overtakes M&A for pipeline expansion, notes…
Buntanetap shows promise in early Parkinson’s with mild dementia: GlobalData
Sub-group data highlights buntanetap’s potential in addressing cognitive and motor symptoms in early Parkinson’s patients with…
Cadila Pharmaceuticals launches Vasograin EC with US FDA-approved formulation for migraine relief
Reformulated Vasograin EC manufactured in USFDA-approved facility; retains leading position in ergotamine segment
Indian Society for Clinical Research appoints Dr Seema Pai as President
Dr Seema Pai to lead ISCR as it marks 20 years, with new appointments to General Secretary and Treasurer roles
Novo Nordisk reports SOUL trial results showing reduced cardiovascular risk with oral semaglutide in…
Phase 3b trial data presented at ACC and published in NEJM highlights cardiovascular outcomes of oral semaglutide in patients with…